 DUBLIN, Ireland, Oct. 01, 2021 GLOBE NEWSWIRE -- Prothena Corporation plc NASDAQ:PRTA, a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hiring two new employees, the compensation committee of the Companys board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 140,000 ordinary shares of the Company. The options have an exercise price per share equal to 70.74, which was the closing trading price on October 1, 2021, the date of the grants. The options will vest over four years, with 25 of the underlying shares vesting on the one-year anniversary of the date of grant and 148th of the underlying shares vesting monthly thereafter over 36 months. The options were granted pursuant to the Companys 2020 Employment Inducement Incentive Plan, which was approved by the Companys board of directors under Rule 5635c4 of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company. 